Skip to content
lifestyle.brightsfuture.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
CASI Pharmaceuticals
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
March 12, 2026
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 15, 2026
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
January 12, 2026